Teva Pharmaceutical Industries Price to Free Cash Flow Ratio 2010-2024 | TEVA

Teva Pharmaceutical Industries current price to free cash flow ratio as of November 25, 2024 is 13.68.

  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2023 was 11.32, a 12.52% increase from 2022.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2022 was 12.94, a 77.8% decline from 2021.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2021 was 58.3, a 380.63% decline from 2020.

Price to free cash flow ratio can be defined as

Teva Pharmaceutical Industries Price to Free Cash Flow Ratio 2010-2024 | TEVA

  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2023 was 11.32, a 12.52% increase from 2022.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2022 was 12.94, a 77.8% decline from 2021.
  • Teva Pharmaceutical Industries average price to free cash flow ratio for 2021 was 58.3, a 380.63% decline from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$11.9B
BridgeBio Pharma (BBIO)$4.4B
Bausch Health Cos (BHC)$2.9B
Amphastar Pharmaceuticals (AMPH)$2.2B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$506M
Personalis (PSNL)$245M
Assembly Biosciences (ASMB)$96M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M